Експресивність реабілітуючих ефектів омега-3 поліненасичених жирних кислот у хворих на цукровий діабет 2-го типу з поліморфними варіантами гена параоксонази
DOI:
https://doi.org/10.24026/1818-1384.2(43).2013.77607Ключові слова:
type 2 diabetes mellitus, paraoxonase gene polymorphism, omega-3 polyunsaturated fatty acidsАнотація
The paper presents data on the basis of which it is firstly proved the role of Q192R genetic variants of the paraoxonase gene (PON1) in the formation of the therapeutic efficacy of omega-3 polyunsaturated fatty acids (Omacor medicine) in patients with type 2 diabetes in relation to new cardiovascular risk factors (insulin resistance, adipocytokines, antioxidant protection) with the identification of QQ genotype as the most reactive. The results confirm the promise of pharmacogenetics as a basis for personalized therapy with a predicted effect of pharmacological intervention.
Посилання
Kozak B.M., Tjota M.I., Close K.L. International Diabetes Federation (IDF) highlights growing global impact of diabetes in 5th edition of the Diabetes Atlas / / Journal of Diabetes. – 2012. – Vol. 4. – P. 8-17. https://doi.org/10.1111/j.1753-0407.2011.00180.x
Тронько М. Д. Пріоритетні проблеми клінічної ендокринології в Україні на сучасному етапі // Здоров'я України. – 2012. – №2-3(18-19). – С. 10-11.
Чернобров А. Д. Довідник основних показників діяльності ендокринологічної служби України за 2012 рік // Ендокринологія. – 2013. – Т. 18, №1(додаток 1). – 36 с.
DeFronzo R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 // Diabetologia. – 2010. – Vol. 53. – P. 1270- 1287. https://doi.org/10.1007/s00125-010-1684-1
Stocker R., Keaney J.F., Jr. Role of oxidative modifications in atherosclerosis // Physiol. Rev. – 2004. – Vol. 84. – P. 1381-1478. https://doi.org/10.1152/physrev.00047.2003
Hayden M.R., Tyagi S.C. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress // Cardiovascular Diabetology. – 2003. – Vol. 2, №2. – P. 1-10.
Bloomgarden Z.T. Insulin resistance, dyslipidemia, and cardiovascular disease // Diabetes Care. – 2007. – Vol. 30, №8. – P. 2164-2170. https://doi.org/10.2337/dc07-zb08
Maritim A.C., Sanders R.A., Watkins J.B. Diabetes, oxidative stress, and antioxidants: a review / / J. Biochem. Mol. Toxicol. – 2003. – Vol. 17. – P. 24-38. https://doi.org/10.1002/jbt.10058
Watson A.D., Berliner J.A., Hama S.Y. et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low-density lipoprotein / / J. Clin. Invest. – 1995. – Vol. 96. – P. 2882-2889. https://doi.org/10.1172/jci118359
Tomas M., Latorre G., Senti M., Marrugata J. The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis // Rev. Esp. Cardiol. – 2004. – Vol. 57, № 6. – P. 557-569. https://doi.org/10.1016/s1885-5857(06)60630-0
Irace C., Cortese C., Fiaschi E. et al. The influence of PON1 192 polymorphism on endothelial function in diabetic subjects with or without hypertension // Hypertens. Res. – 2008. – Vol. 31. – P. 507-513. https://doi.org/10.1291/hypres.31.507
GenBank: https://www.ncbi.nlm.nih.gov/
Zhang B., Eto S., Fan P. et al. Paraoxonase (Pon1) Q192R polymorphism and serum PON1 activity in diabetic patients on maintenance hemodialysis // Clin. Nephrol. – 2003. – Vol. 60, №4. – P. 257-265. https://doi.org/10.5414/cnp60257
Billicke S., Draganov D., Rosenblat M. et al. Human coronary and carotid atherosclerotic lesions: PON1 esterase and human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in peroxidase-like activities // Circulation. – 2000. – Vol. 101. – P. 2510-2517. https://doi.org/10.1161/01.cir.101.21.2510
Sanghera D.K., Saha N., Aston C.E., Kamboh M.I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease // Arterioscler. Thromb. Vasc. Biol. – 1997. – Vol. 17. – P. 1067-1073. https://doi.org/10.1161/01.atv.17.6.1067
Flekac M., Skrha J., Zidkova K. et al. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus // Physiol. Res. – 2008 – Vol. 57. – P. 717-726.
Ranade K., Kirchgessner T.G., Iakoubova O.A. et al. Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke // Stroke. – 2005. – Vol. 36. – P. 2346-2350. https://doi.org/10.1161/01.str.0000185703.88944.7d
Odawara M., Tachi Y., Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus // J. Clin. Endocrinol. Metab. – 1997. – Vol. 82. – P. 2257-2260. https://doi.org/10.1210/jc.82.7.2257
Imai Y., Marita H., Kurihara H. et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases // Atherosclerosis. – 2000. – Vol. 149. – P. 435- 442. https://doi.org/10.1016/s0021-9150(99)00340-8
Voetsch B., Benke K.S., Damasceno B.P. et al. Paraoxonase 192 Gln->Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults // Stroke. – 2002. – Vol. 33. – P. 1459-1464. https://doi.org/10.1161/01.str.0000016928.60995.bd
Billecke S., Draganov D., Counsell R. et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters // Drug Metab. Disposition. – 2000. – Vol. 28, №11. – P. 1335-1342.
Aviram M., Hardak E., Vaya J. et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities // Circulation. – 2000. – Vol. 101, №21. – P. 2510-2517. https://doi.org/10.1161/01.cir.101.21.2510
Katakami N., Sakamoto K., Kaneto H. et al. Combined effect of oxidative stress-related gene polymorphisms on athreosclerosis // Biochem. Biophys. Res. Commun. – 2009. – Vol. 379, №4. – P. 861-865. https://doi.org/10.1016/j.bbrc.2008.12.154
Senti M., Aubo C., Tomas M. Differential effects of smoking on myocardial infraction risk according to the Gln/Arg 192 variants of the human paraoxonase gene // Metabolism. – 2000. – Vol. 49. – P. 557-559. https://doi.org/10.1016/s0026-0495(00)80026-8
Furlong C.E., Cole T.B., Jarvik G.P., Costa, L.G. Pharmacogenomic considerations of the paraoxonase polymorphisms // Pharmacogenomics. – 2002. – Vol. 3. – P. 341-348. https://doi.org/10.1517/14622416.3.3.341
Rodbard H.W., Jellinger P.S. Comment on: Inzucci et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) // Diabetes Care. – 2012. – Vol. 35. – P. 1364-1379. https://doi.org/10.2337/dc12-1184
Сычев Д. А., Раменская Г. В., Игнатьев И. В., Кукес В. Г. Клиническая фармакогенетика: учебное пособие / Под редакцией академика РАМН В. Г. Кукеса и академика РАМН Н. П. Бочкова. - М.: ГЭОТАР. - Медиа, 2007. – 248 с.
Karachentcev Y., Gorshunska M., Jansen E. et al. Omacor attenuated insulin resistance in type 2 diabetes patients // World Diabetes Congress, Dubai, 4-8 December, 2011. – Dubai, 2011. – P. 1403.
Горшунська М. Ю. Вплив омега-3 поліненасичених жирних кислот на класичні та новітні чинники серцево-судинного ризику у хворих на дцукровий діабет 2 типу (огляд літератури та власні результати) // Проблеми ендокринної патології. – 2012. – № 4. – С. 126-134.
Sen-Banerjee S., Siles X., Campos H. Tobacco smoking modifies association between Gln-Arg192 polymorphism of human paraoxonase gene and risk of myocardial infarction // Arterioscler. Thromb. Vasc. Biol. – 2000. – Vol. 20. – P. 2120-2126.
Matthews D.R., Hosker J.P., Rudenski A.S. Homeostasis model assessement: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man // Diabetologia. – 1985. – Vol. 28. – P. 412-419. https://doi.org/10.1007/bf00280883
Katz A., Nambi S.S., Mather K. et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans // J. Clin. Endocrinol. Metabol. – 2000. – Vol. 85. – P. 2402-2410. https://doi.org/10.1210/jc.85.7.2402
Richter R., Furlong C.E. Determination of paraoxonase (PON) status requires more than genotyping // Pharmacogenetics. – 1999. – Vol. 9. – P. 745-753. https://doi.org/10.1097/00008571-199912000-00009
Mackness B., Davies G.K., Turkie W. et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? // Arterioscler. Thromb. Vasc. Biol. – 2001. – Vol. 21. – P. 1451-1457. https://doi.org/10.1161/hq0901.094247
Mastorikou M., Mackness M., Mackness B. Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes // Diabetes. – 2006. – Vol. 55, №11. – P. 3099-3103. https://doi.org/10.2337/db06-0723
Kopprasch S., Pietzsch J., Kuhlisch E. et al. In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance // Diabetes. – 2002. – Vol. 51. – P. 3102-3106. https://doi.org/10.2337/diabetes.51.10.3102
Yamada A., Shoji T., Tahara H. et al. Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population. Metabolism. – 2001. – Vol. 50. – P. 805-811. https://doi.org/10.1053/meta.2001.24215
Nagano Y., Arai H., Kita T. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification // Proc. Natl. Acad. Sci. USA. – 1991. – Vol. 88. – P. 6457-6461. https://doi.org/10.1073/pnas.88.15.6457
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Авторське право (c) 2013 Клінічна ендокринологія та ендокринна хірургія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
